Clinical Trial News and Research

RSS

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Boehringer Ingelheim's investigational tyrosine kinase inhibitor (TKI) BIBF 1120 demonstrated a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF), according to phase II clinical trial results published today online in the New England Journal of Medicine.

22 Sep 2011

African Americans more likely than Caucasians to develop and die from lung cancer

Lung cancer, the leading cause of cancer death in the U.S., takes a particularly heavy toll on African Americans. Despite their lower smoking rates, African Americans are more likely than Caucasians to develop and die from lung cancer.

21 Sep 2011

Study assesses impact of ethnicity on second-line treatment of non-small cell lung cancer

Racial and ethnic minorities are more likely to develop cancer and die from it than the general U.S. population. However, as the next generation of cancer medicines are being evaluated, only 17 percent of clinical trial participants are, in fact, minorities.

21 Sep 2011

Isolating 'bad' cells in rodent experiments may hold key to improving treatment for heart attacks

A UCSF study holds clues to why an emerging clinical trials option for heart attack patients has not been as successful as anticipated. Treatment of human hearts with bone marrow cells has led to limited to no success in improving their heart function even though a similar method has been much more effective in rodents.

21 Sep 2011

Clinical trial to evaluate TAU's stem cell technology for ALS

The ability to produce neuroprotectors, proteins that protect the human brain against neurodegenerative disorders such as Parkinson's and ALS, is the holy grail of brain research. A technology developed at Tel Aviv University does just that, and it's now out of the lab and in hospitals to begin clinical trials with patients suffering from amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

21 Sep 2011

Enrollment commences in Boehringer Ingelheim's TOviTO Phase III combination trial for COPD

Boehringer Ingelheim today announced enrolment has commenced in its TOviTO Phase III clinical trial program. It will investigate tiotropium plus olodaterol in a once-daily fixed-dose combination for the treatment of chronic obstructive pulmonary disease.

21 Sep 2011

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Silence Therapeutics Plc, a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2011.

21 Sep 2011

FSS initiates FlexStent clinical trial for treatment of peripheral arterial disease

Flexible Stenting Solutions Inc. announced today the successful treatment of the first two patients enrolled in the OPEN (Evaluation of Safety and Efficacy of the FlexStent FemorOPopliteal Self-Expanding StENt System) clinical trial.

21 Sep 2011

Beta-blocker drugs may improve survival time for melanoma patients

Beta-blocker drugs, commonly used to treat high blood pressure, may also play a major role in slowing the progression of certain serious cancers, based on a new study.

21 Sep 2011

Niiki Pharma announces positive data from ongoing trial of novel anti-cancer agent NKP-1339

Niiki Pharma Inc. announced interim results from the ongoing Phase I clinical trial of its lead product, NKP-1339. NKP-1339 is a first-in-class transferrin targeted small molecule that down-regulates GRP78, a key regulator of mis-folded protein processing and a tumor survival factor.

20 Sep 2011

Gilead’s Quad Phase 3 clinical study in treatment-naïve HIV-1 patients meets 48-week primary objective

Gilead Sciences, Inc. today announced that the second pivotal Phase 3 clinical trial of its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, being evaluated for HIV-1 infection in treatment-naïve patients, met its primary objective of non-inferiority at week 48 as compared to ritonavir-boosted atazanavir plus Truvada.

20 Sep 2011

Tokai raises $23M in Series D3 financing

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that it has raised $23 million in a Series D3 financing.

20 Sep 2011

Major donors should consider funding for potential malaria vaccine

When the results of a large clinical trial testing the effectiveness of the RTS,S malaria vaccine among children in Africa are made available later this year, "it will be time to start discussing what to do with the vaccine," Orin Levine, executive director of the International Vaccine Access Center at Johns Hopkins University, writes in a Huffington Post opinion piece.

20 Sep 2011

MDA, IMRIS collaborate to advance development of MR guided surgical robot

IMRIS Inc. and MacDonald, Dettwiler and Associates Ltd. today announced an agreement for the final phases of collaborative development of IMRIS's MR guided surgical robot, building on the development work the two companies have completed to date.

20 Sep 2011

Keryx completes enrollment in Zerenex Phase 3 long-term study for hyperphosphatemia

Keryx Biopharmaceuticals today announced completion of patient enrollment in the long-term study component of its Phase 3 registration program of Zerenex, the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.

20 Sep 2011

Infant formulas fortified with LCPUFA are good for developing brains and hearts

University of Kansas scientists have found new evidence that infant formulas fortified with long chain polyunsaturated fatty acids (LCPUFA) are good for developing brains and hearts.

20 Sep 2011

LA BioMed andrologist leads new male contraceptive Phase I clinical study

Christina Wang, M.D., lead investigator at Los Angeles Biomedical Research Institute (LA BioMed) - one of the leading biomedical research institutes in the country - is currently working on a Phase I single dose and multiple dose study that tests the safety and tolerability of a new androgen dimethandrolone undecanoate that is being developed as a potential male contraceptive agent.

20 Sep 2011

Inhibitex initiates INX-189 combination Phase 2 trial in HCV-infected genotype 2/3 patients

Inhibitex, Inc., announced today that it has recently commenced dosing in a 90-patient randomized, placebo controlled, treatment guided, Phase 2 clinical trial to evaluate the safety, tolerability and antiviral activity of INX-189 in combination with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naïve patients.

19 Sep 2011

Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced the first patients have been treated in its Phase 2 clinical trial of EMA401 in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

19 Sep 2011

University of Groningen surgeons perform first fluorescence-guided ovarian cancer surgery

The first fluorescence-guided surgery on an ovarian cancer patient was performed using a cancer cell "homing device" and imaging agent created by a Purdue University researcher.

19 Sep 2011

Clinical Trial News and Research

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

African Americans more likely than Caucasians to develop and die from lung cancer

Study assesses impact of ethnicity on second-line treatment of non-small cell lung cancer

Isolating 'bad' cells in rodent experiments may hold key to improving treatment for heart attacks

Clinical trial to evaluate TAU's stem cell technology for ALS

Enrollment commences in Boehringer Ingelheim's TOviTO Phase III combination trial for COPD

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

FSS initiates FlexStent clinical trial for treatment of peripheral arterial disease

Beta-blocker drugs may improve survival time for melanoma patients

Niiki Pharma announces positive data from ongoing trial of novel anti-cancer agent NKP-1339

Gilead’s Quad Phase 3 clinical study in treatment-naïve HIV-1 patients meets 48-week primary objective

Tokai raises $23M in Series D3 financing

Major donors should consider funding for potential malaria vaccine

MDA, IMRIS collaborate to advance development of MR guided surgical robot

Keryx completes enrollment in Zerenex Phase 3 long-term study for hyperphosphatemia

Infant formulas fortified with LCPUFA are good for developing brains and hearts

LA BioMed andrologist leads new male contraceptive Phase I clinical study

Inhibitex initiates INX-189 combination Phase 2 trial in HCV-infected genotype 2/3 patients

Spinifex initiates EMA401 Phase 2 trial in postherpetic neuralgia

University of Groningen surgeons perform first fluorescence-guided ovarian cancer surgery

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer